Hormone Insight Titelbild

Hormone Insight

Hormone Insight

Von: FWA
Jetzt kostenlos hören, ohne Abo

Über diesen Titel

Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.

Copyright 2024 FWA Wissenschaft
Folgen
  • Episode 002: LDL Under 55 Wins Big, Medicare Covers GLP-1, and Second Weekly Insulin Emerges -- The Week in Diabetes & Endocrinology (April 10, 2026)

    Episode 002: LDL Under 55 Wins Big, Medicare Covers GLP-1, and Second Weekly Insulin Emerges -- The Week in Diabetes & Endocrinology (April 10, 2026)
    Apr 9 2026
    The Week in Diabetes & Endocrinology — Episode 002 | April 10, 2026

    From Hormone Insight (hormoneinsight.com)


    Six stories this week that endocrinologists, diabetologists, and internists need to know.


    TIMESTAMPS:

    0:00 — Introduction & This Week's Stories

    1:30 — EZ-PAVE: LDL Under 55 Beats Under 70 in ASCVD (NEJM)

    7:00 — CMS BALANCE Model: Medicare Covers GLP-1 for Obesity

    11:00 — GZR4: Second Once-Weekly Insulin Beats Glargine AND Degludec

    14:00 — CagriSema NMA at ACC 2026: Best Efficacy AND Tolerability

    16:30 — BP Variability Predicts Dementia in Type 2 Diabetes (ADVANCE)

    19:00 — Blood-Flow Restriction Training Boosts Mitochondria in T2D

    21:00 — Closing Thoughts


    REFERENCES & SHOW NOTES:

    ▸ EZ-PAVE (NEJM): https://doi.org/10.1056/NEJMoa2600283

    ▸ CMS BALANCE Model: https://www.cms.gov/priorities/innovation/innovation-models/balance

    ▸ GZR4 SUPER trials: https://www.prnewswire.com/news-releases/gan--lee-pharmaceuticals-once-weekly-basal-insulin-gzr4-injection-meets-primary-endpoints-in-two-pivotal-phase-3-clinical-trials-super-1-and-super-2-302730104.html

    ▸ CagriSema NMA (DOM): https://doi.org/10.1111/dom.70667

    ▸ ADVANCE BP variability (JAHA): https://doi.org/10.1161/JAHA.125.044061

    ▸ BFRT in T2D (Cell Metab): https://doi.org/10.1016/j.cmet.2025.12.016


    ABOUT THIS PODCAST:

    A weekly evidence-based review of the top stories in diabetes, obesity, thyroid, and endocrinology — modeled on Medscape's "This Week in Cardiology." New episodes every Thursday. For healthcare professionals.


    ▸ Website: https://hormoneinsight.com

    ▸ Full show notes: https://hormoneinsight.com/podcast


    DOWNLOAD THE APP:

    ▸ iOS: https://apps.apple.com/dz/app/hormone-insight/id6749515856

    ▸ Android: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl


    ️ This content is intended for healthcare professionals. It does not constitute medical advice for patients.


    #Endocrinology #DiabetesResearch #LDLcholesterol #EZPAVE #GLP1 #Medicare #CagriSema #WeeklyInsulin #GZR4 #BloodPressure #Dementia #BFRT #ObesityMedicine #MedicalPodcast #HormoneInsight #CME #MedTwitter #DoctorsOfYouTube #EvidenceBasedMedicine #Tirzepatide #Semaglutide
    Mehr anzeigen Weniger anzeigen
    17 Min.
  • The Week in Diabetes and Endocrinology -- April 3, 2026

    The Week in Diabetes and Endocrinology -- April 3, 2026
    Apr 5 2026

    The Week in Diabetes & Endocrinology — Episode 001 | April 3, 2026

    From Hormone Insight (hormoneinsight.com)


    Six stories this week that endocrinologists, diabetologists, and internists need to know.


    TIMESTAMPS:

    0:00 — Introduction & This Week's Stories

    1:30 — Orforglipron (Foundayo) FDA Approval: The Oral GLP-1 Pill — Access-Changer, Not Game-Changer

    7:00 — Semaglutide 7.2 mg (Wegovy HD): 21% Weight Loss, But Watch the Dysesthesia Signal

    11:30 — Insulin Icodec (Awiqli): Once-Weekly Insulin — Sounds Great Until You Think About Sick Days

    16:00 — SURPASS-CVOT Post-Hoc in JAMA Cardiology: Tirzepatide's Cardiorenal NNT of 27

    19:30 — AACE 2026 Type 2 Diabetes Algorithm Update

    21:30 — GLP-1 RAs in Parkinson's Disease: 5 RCTs, 708 Patients, No Signal

    24:00 — Closing Thoughts


    REFERENCES & SHOW NOTES:

    ▸ Orforglipron FDA approval: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

    ▸ Wegovy HD FDA approval: https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide

    ▸ Awiqli FDA approval: https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-awiqli-the-first-and-only-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes-302726839.html

    ▸ Nissen SE et al. JAMA Cardiol 2026 — SURPASS-CVOT cardiorenal post-hoc: https://doi.org/10.1001/jamacardio.2026.0767

    ▸ Nicholls SJ et al. N Engl J Med 2025 — SURPASS-CVOT primary: https://doi.org/10.1056/NEJMoa2505928

    ▸ AACE 2026 T2D Algorithm: https://www.sciencedirect.com/science/article/pii/S1530891X26000224

    ▸ Raza H et al. Brain Behav 2026 — GLP-1 RAs in Parkinson's: https://doi.org/10.1002/brb3.71344


    ABOUT THIS PODCAST:

    A weekly evidence-based review of the top stories in diabetes, obesity, thyroid, and endocrinology — modeled on Medscape's "This Week in Cardiology." New episodes every Thursday. For healthcare professionals.


    ▸ Website: https://hormoneinsight.com

    ▸ Full show notes: https://hormoneinsight.com/podcast


    ️ This content is intended for healthcare professionals. It does not constitute medical advice for patients.


    #Endocrinology #DiabetesResearch #GLP1 #Orforglipron #Foundayo #WegovyHD #Semaglutide #InsulinIcodec #Awiqli #Tirzepatide #SURPASSCVOT #ObesityMedicine #Type2Diabetes #ClinicalTrials #EvidenceBasedMedicine #MedicalPodcast #HormoneInsight #EndocrinologyPodcast #Diabetology #CME #MedTwitter #DoctorsOfYouTube #InternalMedicine #Cardiology #CardiometabolicHealth #WeeklyInsulin #OralGLP1 #ParkinsonsDisease #AACE #PhysicianEducation
    Mehr anzeigen Weniger anzeigen
    24 Min.
  • Early Onset Type 2 Diabetes and Tirzepatide (SURPASS Post Hoc Analysis)

    Early Onset Type 2 Diabetes and Tirzepatide (SURPASS Post Hoc Analysis)
    Jun 14 2025

    In this episode of Hormone Insight, we examine a 2024 post hoc analysis published in Diabetes Care.

    Mehr anzeigen Weniger anzeigen
    1 Min.
Noch keine Rezensionen vorhanden